Name: Cagrilintide + Semaglutide Blend

Alias: CS10, CagriSema Research Compound CAS Registry number: Mixed peptides Sequence: N/A (Two lipidated peptide mixture) Molecular Formula: Mixed formula Molecular Weight: Mixed molecular weight Purity: ≥99% (by HPLC) Appearance: White lyophilized powder Packing: 10mg*10vials (5mg Cagrilintide + 5mg Semaglutide per vial) Product Group: Dual-pathway metabolic composite peptide

Storage Conditions: Store at -20℃ in a dry, dark place; avoid repeated freeze-thaw cycles.

Brief Introduction:

CS10 is a fixed-ratio compound peptide exclusively for laboratory research, composed of equal parts long-acting amylin analog Cagrilintide and GLP-1 receptor agonist Semaglutide. Semaglutide activates GLP-1 signaling to boost glucose-dependent insulin secretion, suppress appetite and slow gastric emptying. Cagrilintide dual activates amylin and calcitonin receptors to enhance central satiety signals, reduce visceral fat and stabilize postprandial blood glucoseNovo Nordi.... The two peptides adopt complementary metabolic pathways with synergistic effects, significantly improving weight loss efficacy, alleviating insulin resistance and regulating lipid metabolism. Widely used in obesity, type 2 diabetes, energy balance and combined peptide pharmacology research.

Main Research Applications:

Glycemic control research: Used in cell and animal models to study dual-pathway blood glucose stabilization and insulin sensitivity improvement. Obesity & appetite regulation research: Suitable for exploring central satiety synergy, food intake reduction and visceral fat degradation mechanisms. Metabolic adaptation research: Applied to investigate inhibition of energy metabolic compensation and sustained weight maintenance effects. Hepatic lipid regulation research: For comparative analysis of liver fat reduction and non-alcoholic fatty liver intervention.

Compound peptide pharmacology research: Study synergistic metabolic benefits of co-activated GLP-1 and amylin receptor pathways.